Cargando…

Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023

COVID-19 is an acute respiratory infectious disease caused by SARS-CoV-2. It was first reported in Wuhan, China in December 2019 and rapidly spread globally in early 2020, triggering a global pandemic. In December 2022, China adjusted the dynamic COVID-zero strategy that lasted for three years. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiang, Zhang, Yuwei, Zhang, Jinbo, Sui, Zongyan, Qu, Xinyi, Wang, Mingrui, Miao, Tingting, Li, Jizhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682769/
https://www.ncbi.nlm.nih.gov/pubmed/38035306
http://dx.doi.org/10.3389/fpubh.2023.1273443
_version_ 1785151046625001472
author Li, Xiang
Zhang, Yuwei
Zhang, Jinbo
Sui, Zongyan
Qu, Xinyi
Wang, Mingrui
Miao, Tingting
Li, Jizhao
author_facet Li, Xiang
Zhang, Yuwei
Zhang, Jinbo
Sui, Zongyan
Qu, Xinyi
Wang, Mingrui
Miao, Tingting
Li, Jizhao
author_sort Li, Xiang
collection PubMed
description COVID-19 is an acute respiratory infectious disease caused by SARS-CoV-2. It was first reported in Wuhan, China in December 2019 and rapidly spread globally in early 2020, triggering a global pandemic. In December 2022, China adjusted the dynamic COVID-zero strategy that lasted for three years. The number of positive cases in China increased rapidly in the short term. Weihai was also affected during this period. We conducted genomic surveillance of SARS-CoV-2 variants in Weihai during this period, hoping to understand the changes in the genomic characteristics of SARS-CoV-2 before and after the adjustment of the epidemic policy. In this study,we collected SARS-CoV-2 positive samples from March 2022 to March 2023 in Weihai and performed SARS-CoV-2 whole genome sequencing on these samples using next-generation sequencing technology. we obtained a total of 704 SARS-CoV-2 whole genome sequences, and selected 581 high-quality sequences for further analysis. The analysis results showed that from March 2022 to November 2022, before the adjustment of epidemic policy, the COVID-19 cases in Weihai were mainly from four local clusters,which were caused by four variants, including BA.2,BA.1.1,P.1.15 and BA.5.2.1. Phylogenetic analysis showed that: In the same cluster,the sequences between each other were highly homologous, and the whole genome sequence were almost identical. After December 2022, the epidemic policy was adjusted, BF.7 and BA.5.2 became the dominant variants in Weihai, consistent with the main domestic strains in China during the same period. Phylodynamic analysis showed that BF.7 and BA.5.2 had a large amount of genetic diversities in December, and the effective population size of BF.7 and BA.5.2 also showed explosive growth in December. In conclusion, we reported the composition and dynamic trend of SARS-CoV-2 variants in Weihai from March 2022 to March 2023. We found that there have been significant changes in the variants and expansion patterns of SARS-CoV-2 before and after the adjustment of epidemic policies. But the dominant variants in Weihai were the same as the SARS-CoV-2 variants circulating globally at the same time and we found no persistently dominant variants or new lineages during this period.
format Online
Article
Text
id pubmed-10682769
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106827692023-11-30 Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023 Li, Xiang Zhang, Yuwei Zhang, Jinbo Sui, Zongyan Qu, Xinyi Wang, Mingrui Miao, Tingting Li, Jizhao Front Public Health Public Health COVID-19 is an acute respiratory infectious disease caused by SARS-CoV-2. It was first reported in Wuhan, China in December 2019 and rapidly spread globally in early 2020, triggering a global pandemic. In December 2022, China adjusted the dynamic COVID-zero strategy that lasted for three years. The number of positive cases in China increased rapidly in the short term. Weihai was also affected during this period. We conducted genomic surveillance of SARS-CoV-2 variants in Weihai during this period, hoping to understand the changes in the genomic characteristics of SARS-CoV-2 before and after the adjustment of the epidemic policy. In this study,we collected SARS-CoV-2 positive samples from March 2022 to March 2023 in Weihai and performed SARS-CoV-2 whole genome sequencing on these samples using next-generation sequencing technology. we obtained a total of 704 SARS-CoV-2 whole genome sequences, and selected 581 high-quality sequences for further analysis. The analysis results showed that from March 2022 to November 2022, before the adjustment of epidemic policy, the COVID-19 cases in Weihai were mainly from four local clusters,which were caused by four variants, including BA.2,BA.1.1,P.1.15 and BA.5.2.1. Phylogenetic analysis showed that: In the same cluster,the sequences between each other were highly homologous, and the whole genome sequence were almost identical. After December 2022, the epidemic policy was adjusted, BF.7 and BA.5.2 became the dominant variants in Weihai, consistent with the main domestic strains in China during the same period. Phylodynamic analysis showed that BF.7 and BA.5.2 had a large amount of genetic diversities in December, and the effective population size of BF.7 and BA.5.2 also showed explosive growth in December. In conclusion, we reported the composition and dynamic trend of SARS-CoV-2 variants in Weihai from March 2022 to March 2023. We found that there have been significant changes in the variants and expansion patterns of SARS-CoV-2 before and after the adjustment of epidemic policies. But the dominant variants in Weihai were the same as the SARS-CoV-2 variants circulating globally at the same time and we found no persistently dominant variants or new lineages during this period. Frontiers Media S.A. 2023-11-14 /pmc/articles/PMC10682769/ /pubmed/38035306 http://dx.doi.org/10.3389/fpubh.2023.1273443 Text en Copyright © 2023 Li, Zhang, Zhang, Sui, Qu, Wang, Miao and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Li, Xiang
Zhang, Yuwei
Zhang, Jinbo
Sui, Zongyan
Qu, Xinyi
Wang, Mingrui
Miao, Tingting
Li, Jizhao
Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023
title Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023
title_full Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023
title_fullStr Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023
title_full_unstemmed Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023
title_short Genomic surveillance of SARS-CoV-2 in Weihai, China, march 2022 to march 2023
title_sort genomic surveillance of sars-cov-2 in weihai, china, march 2022 to march 2023
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682769/
https://www.ncbi.nlm.nih.gov/pubmed/38035306
http://dx.doi.org/10.3389/fpubh.2023.1273443
work_keys_str_mv AT lixiang genomicsurveillanceofsarscov2inweihaichinamarch2022tomarch2023
AT zhangyuwei genomicsurveillanceofsarscov2inweihaichinamarch2022tomarch2023
AT zhangjinbo genomicsurveillanceofsarscov2inweihaichinamarch2022tomarch2023
AT suizongyan genomicsurveillanceofsarscov2inweihaichinamarch2022tomarch2023
AT quxinyi genomicsurveillanceofsarscov2inweihaichinamarch2022tomarch2023
AT wangmingrui genomicsurveillanceofsarscov2inweihaichinamarch2022tomarch2023
AT miaotingting genomicsurveillanceofsarscov2inweihaichinamarch2022tomarch2023
AT lijizhao genomicsurveillanceofsarscov2inweihaichinamarch2022tomarch2023